Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer

Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer

Background: The aim of this study was to improve activity over single human epidermal growth factor receptor 2 (HER2)-blockade sequential neaodjuvant regimens for HER2-positive breast cancer, by exploiting the concomitant administration of trastuzumab, taxane and anthracycline, while restraining car...

Full description

Bibliographic Details
Main Authors: Andrea Rocca, Pietro Cortesi, Laura Cortesi, Lorenzo Gianni, Federica Matteucci, Lorenzo Fantini, Antonio Maestri, Donata Casadei Giunchi, Luigi Cavanna, Rosa Ciani, Fabio Falcini, Antonella Bagni, Elena Meldoli, Monia Dall’Agata, Roberta Volpi, Daniele Andreis, Oriana Nanni, Annalisa Curcio, Leonardo Lucchi, Dino Amadori, Anna Fedeli
Format: Article
Language:English
Published: SAGE Publishing 2021-02-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835920985632

Internet

https://doi.org/10.1177/1758835920985632

Similar Items